11,237 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 11,237 shares of the biopharmaceutical company’s stock, valued at approximately $338,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Blue Trust Inc. grew its stake in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 371 shares during the period. Smartleaf Asset Management LLC lifted its holdings in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp grew its position in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 1,737 shares during the period. Synergy Asset Management LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter worth about $75,000. Finally, GAMMA Investing LLC raised its position in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 2,171 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Price Performance

TGTX stock opened at $42.99 on Friday. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.15. The firm has a market capitalization of $6.75 billion, a PE ratio of -429.86 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business has a 50 day simple moving average of $33.17 and a 200-day simple moving average of $29.68.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TGTX shares. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.